BioCryst Pharmaceuticals | BCRX - 流动资产



金融业
股票价格
USD
资产
USD 465.05M
现金及等价物
USD 171.59M
销售成本
USD 9.52M
流动资产
USD 373.63M
流动负债
USD 195.39M
债务
USD 828.6M
股息收益率
0
EBIT
USD 260.39M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 1.17
股本和储备
USD -553.84M
销售毛利
USD 153.05M
债务利息支出
USD 14.14M
利息收入
USD -0.13
贷款资金
USD 395.2M
市值
USD 1.93B
净收入
USD 245.85M
营业费用
USD -553.84M
营业利润
USD 260.39M
普通股股本
USD 213.06M
PE价格收益
6.06
税前利润
USD 248.02M
销售收入
USD 406.56M
销售和管理费用
USD 95.78M
股票
USD 5.99M
贸易债权人
USD 10.96M
应收帐款人
USD 106.82M


流动资产 更改 日
Alnylam Pharmaceuticals USD 4.22B 168.65M 2026-03
BioCryst Pharmaceuticals USD 373.62M 30.72M 2026-03
Chugai Pharma JPY 1.7T 164.75B 2026-06
Daiichi Sankyo JPY 2.1T 218.5B 2025-12
DBV Technologies USD 201.9M 44.8M 2026-06
Enanta Pharmaceuticals USD 198.68M 5.65M 2025-12
Gilead Sciences USD 18.64B 1.25B 2026-03
GlaxoSmithKline GBP 17.76B 251M 2026-03
Glaxosmithkline GBP 17.76B 5.83B 2026-03
Incyte USD 5.48B 460.36M 2026-03
Ionis Pharmaceuticals USD 2.94B 52M 2026-03
Karyopharm Therapeutics USD 103.15M 13.4M 2025-12
Neurocrine Biosciences USD 2.44B 86.6M 2026-03
Novavax USD 850.82M 127.46M 2026-03
PTC Therapeutics USD 2.25B 19.94M 2026-03
Regeneron Pharmaceuticals USD 18.21B 187.3M 2026-03
Roche Holding CHF 35.44B 3.29B 2026-06
Sarepta Therapeutics USD 2.31B 228.06M 2026-03
Ultragenyx Pharmaceutical USD 657M 294M 2026-03
Vertex Pharmaceuticals USD 11.73B 529.3M 2026-03